Protalix BioTherapeutics Inc (AMEX:PLX)
$ 1.1 -0.15 (-12%) Market Cap: 80.65 Mil Enterprise Value: 62.37 Mil PE Ratio: 55.00 PB Ratio: 2.39 GF Score: 60/100

Protalix Biotherapeutics Inc Updates On PRX-102 - Corporate Call Transcript

Jun 02, 2021 / 05:30AM GMT
Release Date Price: $2.48 (-16.78%)
Operator

Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Conference Call regarding the clinical development of PRX-102 for the treatment of Fabry disease. As a reminder, this conference call is being recorded.

I will now turn the conference over to our host, Mr. Chuck Padala of LifeSci Advisors, Investor Relations. You may begin your conference.

Charles Padala

All right. Thank you, Rob. Welcome to the Protalix Conference Call regarding the clinical development of PRX-102 for the treatment of Fabry disease. With me today are Dror Bashan, President and CEO of Protalix; and Eyal Rubin, Chief Financial Officer. Mr. Bashan and Mr. Rubin are joined today by Mr. Ulrich Granzer, PhD, of Granzer Regulatory Consulting & Services. The agency provides Protalix and Chiesi with consulting services related to drug development and regulatory affairs.

Dr. Granzer is a founding member of the German Association of Regulatory Affairs, where he is the current President of the Board and Co-Founder of the European Union Regulatory Affairs Group

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot